Valuation: Alumis Inc.

Market Cap 3.13B 2.68B 2.51B 2.3B 4.31B 299B 4.36B 29.62B 11.55B 150B 11.75B 11.49B 497B P/E 2026 *
-7.43x
P/E 2027 * -8.64x
Enterprise Value 2.41B 2.07B 1.93B 1.77B 3.32B 231B 3.37B 22.84B 8.91B 116B 9.06B 8.86B 384B EV / Sales 2026 *
377x
EV / Sales 2027 * 107x
Free-Float
96.45%
Yield 2026 *
-
Yield 2027 * -
1 day+5.73%
1 week-4.50%
Current month-14.44%
1 month-19.57%
3 months+9.02%
6 months-13.59%
Current year+147.64%
1 week 22.03
Extreme 22.03
25.94
1 month 22.03
Extreme 22.03
29.28
Current year 7.85
Extreme 7.85
31.35
1 year 3.76
Extreme 3.76
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 23/09/2021
Director of Finance/CFO 60 01/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 63 01/05/2021
Director/Board Member 60 01/06/2021
Chairman 61 23/09/2021
Date Insider Type Main position Quantity % Market Cap.
03/08/26 Sell

Chief Technology Officer

-2,447 0.0020%
03/08/26 Sell

Executive/Senior Manager

-2,692 0.0022%
03/08/26 Sell

General Counsel

-1,364 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
+5.73%-4.50%+425.43% - 3.13B
-3.00%+2.27%+77.60%+109.33% 72.12B
+1.90%+23.53%+56.60%+97.76% 65.85B
+5.12%+25.22%+5.24%-0.82% 29.28B
+0.55%+1.64%-5.15%+471.68% 27.47B
+2.74%+12.98%+62.84%+28.14% 26.7B
+0.47%+6.12%+36.66%-13.79% 20.06B
+1.82%-6.67%+247.46%+393.10% 18.22B
+0.94%+3.36%+18.55%+532.94% 16.4B
+0.73%+5.54%+39.71%+153.07% 13.4B
Average +1.70%+7.08%+96.49%+196.82% 29.26B
Weighted average by Cap. +0.80%+9.33%+62.96%+157.80%

Financials

2026 *2027 *
Net sales 6.4M 5.48M 5.13M 4.7M 8.81M 612M 8.93M 60.62M 23.64M 308M 24.04M 23.51M 1.02B 24.33M 20.85M 19.5M 17.85M 33.51M 2.33B 33.95M 230M 89.86M 1.17B 91.37M 89.39M 3.87B
Net income -426M -365M -342M -313M -587M -40.79B -595M -4.04B -1.57B -20.49B -1.6B -1.57B -67.78B -409M -350M -328M -300M -563M -39.1B -570M -3.87B -1.51B -19.64B -1.53B -1.5B -64.97B
Net Debt -716M -613M -574M -525M -986M -68.51B -999M -6.78B -2.64B -34.41B -2.69B -2.63B -114B -514M -440M -412M -377M -708M -49.17B -717M -4.87B -1.9B -24.7B -1.93B -1.89B -81.7B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
238
Date Price Change Volume
21/08/26 $24.17 +5.73% 934,814
20/08/26 $22.86 -4.71% 949,389
19/08/26 $23.99 -3.58% 937,934
18/08/26 $24.88 -2.43% 661,654
17/08/26 $25.50 +0.75% 843,995
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
24.17USD
Average target price
40.33USD
Spread / Average Target
+66.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock